SMAD2 and renal fibrosis: Indeed, as a therapeutic approach to reversing fibrosis, interference with SMAD2 acetylation either by the DAXX transcription factor, as shown in hepatocytes [51], or by the p300/CBP inhibitor garcinol, as shown in a nondiabetic renal fibrosis model [26], can be considered.